Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28036128 | 0.86 | JAK2 (0.47) | METJAK2MAP4K3ALK | |
| SCHEMBL28643808 | 0.84 | MET (0.47) | METJAK2MAP4K3FYNALK | |
| SCHEMBL28645868 | 0.84 | MET (0.46) | METJAK2MAP4K3ALKMAP4K4 | |
| SCHEMBL28035735 | 0.82 | JAK2 (0.47) | METJAK2MAP4K3FYNALK | |
| SCHEMBL28515206 | 0.81 | JAK2 (0.62) | METJAK2MAP4K3 | |
| SCHEMBL28642048 | 0.81 | MET (0.46) | METJAK2MAP4K3FYNALK | |
| SCHEMBL12004389 | 0.80 | MET (0.44) | METJAK2MAP4K3ALK | |
| SCHEMBL28628304 | 0.79 | MET (0.45) | METJAK2MAP4K3FYNALK | |
| Hydrochloric Acid SCHEMBL15779562 | 0.79 | MET (0.53) | METJAK2MAP4K3ALK | |
| SCHEMBL1823431 | 0.79 | MET (0.57) | METJAK2MAP4K3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150250780-A1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-09-10 | — | — | US | disclosed |
| US-9011865-B2 | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer | Pierre Gabre Medicament (FR) | 2015-04-21 | — | — | US | disclosed |
| US-20140186356-A1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2014-07-03 | — | — | US | disclosed |
| EP-2143441-A1 | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer | Pierre Fabre Medicament (FR) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250780-A1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | MET, HGF, EGFR | MET 1/4885JAK2 330/4885MAP4K3 1607/4885 |
| US-20140186356-A1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | MET, HGF, EGFR | MET 1/4885JAK2 330/4885MAP4K3 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.